Freeze-Drying Equipment Market - Segmentation, Major Players & Geographical Analysis

The Research Report on “Freeze-Drying/Lyophilization Market by Type (Tray, Shell, Manifold), Scale of operation (Industrial, Lab, Pilot), Application (Food, Pharma & Biotech), Accessories (Loading & Unloading, Monitoring, Vacuum Systems, Drying Chambers) – Global Forecast to 2025″, the global freeze-drying equipment market is projected to reach USD 7.3 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 8.2% from 2020 to 2025.

Growth Drivers: Increasing demand for food preservation;

Lyophilization equipment is used for the preservation of various food products, such as fruits and vegetables, meat, fish, herbs and food flavorings, ice creams, and coffee. Freeze-dried foods do not need to be refrigerated or preserved with chemicals and can be reconstituted quickly and easily by adding water. Another major advantage of freeze-drying of food is its ability to produce clean, whole, and nutritious food ingredients with a highly prolonged shelf life (making food products versatile and accessible).

The use of freeze-dried foods is increasing for astronauts and military personnel, as conventional drying methods have major disadvantages. For instance, the high temperatures used can cause chemical or physical changes in food products, and their overall quality is not on par with freeze-dried food products. Considering these advantages, the use of freeze-drying as a food preservation technique is increasing across the globe.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=24018886

Industry Segmentation In Detailed:

The tray-style freeze dryers segment accounted for the largest market share in 2019.

Based on type, the freeze-drying/lyophilization equipment market is classified into tray-style freeze dryers, manifold freeze dryers, and shell (rotary) freeze dryers. In 2019, the tray-style freeze dryers segment accounted for the largest share of 72.1%. This segment is also estimated to grow at the highest CAGR of 8.2% during the forecast period. Growth in this market is largely driven by factors such as the increasing demand for contract manufacturing and contract lyophilization services in the pharmaceutical industry, the growing commercialization of labile drugs, and the rising demand for freeze-dried food products. Tray-style freeze dryers are also larger than manifold and rotary freeze dryers, enabling them to dry products in bulk.

The industrial-scale lyophilization equipment segment accounted for the largest market share in 2019.

Based on scale of operation, the freeze-drying/lyophilization equipment market is segmented into industrial-scale lyophilization equipment, pilot-scale lyophilization equipment, and laboratory-scale lyophilization equipment. In 2019, the industrial-scale lyophilization equipment segment accounted for the largest share of 68.2% of the market. The large share of this market segment can be attributed to the high standard of quality provided by industrial-scale lyophilization equipment. Industrial-scale lyophilization equipment can also be customized as per process requirements.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=24018886

Leading Key Players and Analysis:

Some of the prominent players in Freeze-Drying Market are GEA Group (Germany), Azbil Corporation (Japan), Shanghai Tofflon Science Technology Co., Ltd. (China), IMA S.p.A. (Italy), SP Industries, Inc. (US), HOF Enterprise Group (Germany), Labconco Corporation (US), Martin Christ Gefriertrocknungsanlagen GmbH (Germany), Millrock Technology, Inc. (US), and OPTIMA Packaging Group GmbH (Germany).

Geographical Analysis in Detailed:

The freeze-drying/lyophilization equipment market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2019, the Asia Pacific accounted for the largest share of 34.6% of the market and is projected to register the highest CAGR of 10.4% during the forecast period. The large share of the Asia Pacific regional segment can be attributed to the rising number of investments in this region, growth in R&D expenditure, and geographic expansion of lyophilization equipment companies in this region. Moreover, the presence of major players in the lyophilization market in the APAC region and the expansion of the manufacturing units of leading pharma companies in this region is expected to boost the market growth in this region in the forecast period.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=24018886

Regenerative Medicine Market Size, Share, Outlook, Industry Analysis Report 2020

The Research Report on "Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025", is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9%.

Growth Driver: Growing prevalence of chronic diseases, genetic disorders, and cancer;

Over the last few decades, the incidence and prevalence of chronic diseases such as CVD, cancer, diabetes, ulcers, and genetic disorders such as cystic fibrosis have increased significantly across the globe. Diabetes and obesity can result in the increased incidence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, which require treatments and incur exorbitant medical expenses.

Growth Opportunity: Implementation of the 21st Century Cures Act;

The 21st Century Cures Act was signed into law in the US in December 2016. Among other objectives, this new law has been enacted to advance regenerative medicine research and medical innovation and covers various provisions that may impact the development and approval of several products in the coming years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579

Industry Segmentation In Detailed:

The tissue-engineered products segment accounted for the largest share of the regenerative medicine market, by product segment, in 2019

Based on products, segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The tissue-engineered products segment accounted for the largest share in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment to register the highest growth rate during the forecast period

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=65442579

Leading Key Players and Analysis:

The major players operating in Regenerative Medicine Market are 3M (US), Allergan plc (Ireland), Amgen, Inc. (US), Aspect Biosystems (Canada), bluebird bio (US), Kite Pharma (US), Integra LifeSciences Holdings Corporation (US), MEDIPOST Co., Ltd. (South Korea), Medtronic plc (Ireland), Anterogen Co., Ltd. (South Korea), MiMedx Group (US), Misonix (US), Novartis AG (Switzerland), Organogenesis Inc. (US), Orthocell Limited (Australia), Corestem, Inc. (South Korea), Spark Therapeutics (US), APAC Biotech (India).

Novartis AG (Switzerland) Novartis AG is one of the the largest player in the regeneartive medicine market in 2019. In order to maintain its position in the market, the company has been focusing on the innovations, and breakthrough product approvals for the treatment of cancer. For instance, in August 2017, Novartis received the FDA approval for CAR-T cell therapy, Kymriah (CTL019), which is used for the treatment of cancer. Kymriah got the EU approval in August 2018. Novartis also focused on the inorganic strategies in order to enhance their dominance in the regenerative medicine market. For instance, Novartis received EU approval for one-time gene therapy, Luxturna, developed by Spark Therapeutics, to restore vision in people with rare and genetically-associated retinal disease.

Geographical Analysis in Detailed:

The regenerative medicine market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the market. The growth in the North American market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=65442579

MarketsandMarkets analysis says that a Potential Opportunity Worth $50 Bn is opening up in Genomics

As Genome Sequencing heads to $100 Direct-to-Consumer, a potential opportunity worth $50 Bn is expected to open up, leading to a million terabytes of genome data by 2025.

The genome sequencing market will reach $25 Bn by 2026, further intensified by COVID-19, and oncology and rare disease diagnostics coupled with pan genome studies. Adjacent markets of data storage, high performance computing (HPC), lab automation, and AI are anticipated to see unlocking of a further $20 Bn.

According to MarketsandMarkets analysis,

• $50 Bn of potential opportunity is opening up as genome sequencing heads to $100 direct-to-consumer, which was one of the most talked-about trends in 2021.
• The global genomic studies and projects comprising advanced genetic sequencing is expected to drive better clinical decision-making in the coming years, presenting lucrative growth opportunities to NGS companies.
• Additionally, the life sciences market is witnessing an increased adoption of AI, personalized healthcare, gene editing, etc., which is likely to disrupt the demand for genomics, in turn impacting the growth of the market.
• The increasing demand for sequencing and bioinformatics in diagnostics is predicted to disrupt the demand for IVD over the next few years.

MarketsandMarkets is focused on high-growth, niche markets, such as AI in genomics, spatial genomics & transcriptomics, liquid biopsy, single-cell analysis, and related markets, providing a comprehensive understanding of the entire genomics ecosystem through the World’s First Market Intelligence Cloud, 'KnowledgeStore'. It helps find blind spots in clients’ revenue decisions because of interconnections and unknowns that impacting clients and their client’s clients.

For more details, please visit: https://www.marketsandmarkets.com/practices/genomics-new.asp

Press Release: https://www.marketsandmarkets.com/PressReleases/genomics.asp